A gentler treatment for children whose leukemia has come back could boost survival and quality of life, a study led by a UCL ...

Results from the MagnetisMM-5 study showed that Elrexfio significantly improved progression-free survival, which means ...

A new approach achieved remission rates of 92% and long-term survival was comparable to children on more intensive plans.

Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...

A prespecified interim analysis showed statistically significant PFS improvement with elranatamab versus ...

Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T therapy candidate ...

New treatment option for rare, life-altering pediatric brain tumors Less than 10% of new medicine approvals over the past five years have focused ...

The data showed notable responses, even among patients living with chronic lymphocytic leukemia (CLL) who had previous exposure to B-cell receptor–associated kinase inhibitors, the authors said.

Please provide your email address to receive an email when new articles are posted on . The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia ...

Carvykti is a B-cell maturation antigen-directed genetically modified autologous chimeric antigen receptor T-cell therapy. The Food and Drug Administration (FDA) has approved Carvykti ® ...

Revuforj is approved for relapsed or refractory acute leukemia with KMT2A translocation in patients aged 1 year and older. The AUGMENT-101 trial showed a 21.2% complete remission rate with a median ...